ARDT
Ardent Health Partners, LLC
ARDT's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ARDT overall, supported by stronger fundamentals and stronger valuation.
ARDT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
ARDT's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ARDT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.5x | $6.75 | -62% |
| Fair | 9x | $9.25 | -48% |
| Forward | 15x | $17.68 | — |
| Current | 17x | $17.68 | — |
| Expensive | 20x | $20.97 | +19% |
Historical ranges are pointers, not guarantees.
ARDT has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ARDT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect ARDT's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ARDT on the outlook, with more favorable revenue expectations.
ARDT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.21 | +17% |
| Q3 2026 | $1.03 | -30% |
| Q2 2026 | $0.55 | -70% |
| Q1 2026 | $0.95 | -42% |
| Q4 2025 | $0.96 | -38% |
| Q3 2025 | $1.47 | +119% |
| Q2 2025 | $1.83 | +190% |
| Q1 2025 | $1.65 | +217% |
| Q4 2024 | $1.55 | +343% |
ARDT's earnings per share have fallen from their peak: $1.03 over the past year, against $1.83 in mid-2025.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ARDT on earnings, with more consistent year-over-year improvement.
ARDT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +3.1% |
| Q2 2026 | $1.6B | -1.4% |
| Q1 2026 | $1.6B | +7% |
| Q4 2025 | $1.6B | -0.1% |
| Q3 2025 | $1.6B | +8.8% |
| Q2 2025 | $1.6B | +12% |
| Q1 2025 | $1.5B | +4% |
| Q4 2024 | $1.6B | +19% |
ARDT's revenue grew through 2024 and has held roughly level since: $1.6B last quarter, up 3.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5% | +5.1 points |
| Q2 2026 | 2.7% | -4.8 points |
| Q1 2026 | 4.7% | -0.3 points |
| Q4 2025 | 5.8% | -4.7 points |
| Q3 2025 | -0.1% | -4.1 points |
| Q2 2025 | 7.4% | +1.8 points |
| Q1 2025 | 5% | -0.3 points |
| Q4 2024 | 10% | -2.4 points |
ARDT's operating margin was 5% last quarter, up 5.1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ARDT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ARDT on profitability, with a higher operating margin.
ARDT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $121.9M | -21% |
| Q2 2026 | $196.7M | +67% |
| Q1 2026 | -$60.2M | -$35.4M |
| Q4 2025 | $223.4M | +87% |
| Q3 2025 | $154.4M | +72% |
| Q1 2025 | -$24.8M | +$13.7M |
| Q4 2024 | $119.6M | +1090% |
| Q3 2024 | $89.7M | +41% |
ARDT generated $482M in free cash flow over the past year, up 31% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ARDT on cash flow, with more consistent year-over-year improvement.
ARDT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -1.3M shares |
| 1 year | +0.3% | +478K shares |
| 3 years | +0.5% | +741K shares |
| 5 years | +86% | +65.7M shares |
ARDT has 142M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $11M |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2018 | — |
| Q3 2018 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ARDT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ARDT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 1.0x | Healthy |
| Q1 2026 | 1.1x | Healthy |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.0x | Very low |
| Q2 2025 | 1.0x | Healthy |
| Q1 2024 | 5.1x | High |
| Q4 2023 | 5.5x | High |
ARDT has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ARDT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 82.1 | Overbought |
| Stochastic | 88.7 | Overbought |
ARDT's weekly RSI is 82 (overbought) and its Stochastic is 89 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ARDT PE vs Healthcare Sector
| Metric | ARDT | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 34% below |
| PE % | 75 | 54 | 21 pts above |
ARDT has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ARDT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.9 | 37% above |
| 20 week MA | $11.6 | 52% above |
| 50 week MA | $10.1 | 74% above |
| 100 week MA | $11.8 | 50% above |
LLY has stronger trend alignment. ARDT is above 4 of 4 weekly averages versus LLY above 5 of 5.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
ARDT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $17.3 | $16.9 | -2.3% |
| 2025 | $16.9 | $9.22 | -45% |
| 2026 YTD | $9.22 | $17.7 | +92% |
ARDT has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.